Monksdream
1 month ago
Good morning! In the latest GLP-1 news, the FDA reported last week that Eli Lillyβs weight loss and diabetes drug Mounjaro is no longer facing a shortage. This means pharmacy companies that have been compounding the medication, a process that uses the same ingredients and is only allowed in times of shortages, can no longer do so. Novo Nordiskβs Ozempic and Wegovy are not affected by this, and will likely continue to be distributed by compounding pharmacies, including Hims and Hers.